UNITY Biotechnology to Participate in the Cowen 42nd Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at 11:10 a.m. ET.

The presentation will be available through the Cowen conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event.

About UNITY

UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter and LinkedIn.

Media Contact
Canale Communications
Jason Spark
Jason.spark@canalecomm.com

Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
jallaire@lifesciadvisors.com

Source: Unity Biotechnology, Inc.